Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBU NASDAQ:IMDX NASDAQ:MREO NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.60-3.9%$2.05$1.04▼$3.54$164.64M2.331.75 million shs2.29 million shsIMDXOncocyte$5.61+3.3%$4.82$2.33▼$8.51$175.34M1.79288,683 shs389,868 shsMREOMereo BioPharma Group$0.31-2.2%$0.30$0.20▼$3.05$49.77M0.336.91 million shs2.12 million shsUNCYUnicycive Therapeutics$7.25-5.7%$7.40$3.71▼$8.74$210.65M1.73776,372 shs943,384 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-7.26%-19.81%-18.23%-11.70%+40.68%IMDXOncocyte-5.73%-17.10%+9.04%+10.59%+542,999,900.00%MREOMereo BioPharma Group+2.33%-1.95%+26.75%-19.22%-88.23%UNCYUnicycive Therapeutics0.00%+3.50%-5.88%+12.59%+22.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$1.60-3.9%$2.05$1.04▼$3.54$164.64M2.331.75 million shs2.29 million shsIMDXOncocyte$5.61+3.3%$4.82$2.33▼$8.51$175.34M1.79288,683 shs389,868 shsMREOMereo BioPharma Group$0.31-2.2%$0.30$0.20▼$3.05$49.77M0.336.91 million shs2.12 million shsUNCYUnicycive Therapeutics$7.25-5.7%$7.40$3.71▼$8.74$210.65M1.73776,372 shs943,384 shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences-7.26%-19.81%-18.23%-11.70%+40.68%IMDXOncocyte-5.73%-17.10%+9.04%+10.59%+542,999,900.00%MREOMereo BioPharma Group+2.33%-1.95%+26.75%-19.22%-88.23%UNCYUnicycive Therapeutics0.00%+3.50%-5.88%+12.59%+22.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences 2.75Moderate Buy$8.67439.98% UpsideIMDXOncocyte 2.00Hold$12.00114.86% UpsideMREOMereo BioPharma Group 2.25Hold$3.25948.39% UpsideUNCYUnicycive Therapeutics 2.67Moderate Buy$24.75238.81% UpsideCurrent Analyst Ratings BreakdownLatest MREO, IMDX, UNCY, and CRBU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/9/2026UNCYUnicycive Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026UNCYUnicycive Therapeutics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSpeculative Buy$15.00 ➝ $18.005/27/2026UNCYUnicycive Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.005/13/2026UNCYUnicycive Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $37.005/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.005/11/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $11.005/1/2026UNCYUnicycive Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.004/20/2026CRBUCaribou Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026CRBUCaribou Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$11.20M14.21N/AN/A$1.31 per share1.23IMDXOncocyte$4.05M44.53N/AN/A($1.10) per share-5.08MREOMereo BioPharma Group$500K98.96N/AN/A$0.26 per share1.19UNCYUnicycive TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$148.12M-$1.42N/AN/AN/A-1,189.14%-84.17%-60.51%8/11/2026 (Estimated)IMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/AMREOMereo BioPharma Group-$41.88M-$0.05N/A15.50N/AN/A-81.28%-70.45%8/11/2026 (Estimated)UNCYUnicycive Therapeutics-$26.56M-$2.21N/A0.90N/AN/A-134.69%-84.51%8/13/2026 (Estimated)Latest MREO, IMDX, UNCY, and CRBU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A5/12/2026Q1 2026UNCYUnicycive Therapeutics-$0.4589-$0.54-$0.0811-$0.54$11.11 millionN/A5/7/2026Q1 2026CRBUCaribou Biosciences-$0.33-$0.26+$0.07-$0.26$2.21 million$2.40 million3/30/2026Q4 2025UNCYUnicycive Therapeutics-$0.46-$0.82-$0.36-$0.82$0.52 millionN/A3/26/2026Q4 2025IMDXOncocyteN/A-$0.27N/A-$0.72N/A$1.14 million3/20/2026Q4 2025MREOMereo BioPharma Group-$0.01-$0.01N/A-$0.05$5.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A6.226.22IMDXOncocyteN/A2.542.51MREOMereo BioPharma GroupN/A6.486.48UNCYUnicycive TherapeuticsN/A2.402.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%IMDXOncocyte55.35%MREOMereo BioPharma Group62.83%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences8.54%IMDXOncocyte2.05%MREOMereo BioPharma Group6.50%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences10099.18 million90.71 millionOptionableIMDXOncocyte12032.29 million31.63 millionN/AMREOMereo BioPharma Group40159.62 million149.24 millionOptionableUNCYUnicycive Therapeutics927.39 million24.46 millionNot OptionableMREO, IMDX, UNCY, and CRBU HeadlinesRecent News About These CompaniesUnicycive Expands At-The-Market Equity Offering ProgramJune 5, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)June 5, 2026 | theglobeandmail.comUnicycive Therapeutics: A Catalyst Play With Real Fundamental UpsideMay 21, 2026 | seekingalpha.comUnicycive Therapeutics Inc Ordinary Shares UNCYMay 16, 2026 | morningstar.comMUnicycive Therapeutics (UNCY) price target decreased by 23.53% to 32.20May 14, 2026 | msn.comUnicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing?May 14, 2026 | finance.yahoo.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | finanznachrichten.deUnicycive Therapeutics Provides Update on FDA Review and Financial Results Ahead of OLC Launch PreparationsMay 12, 2026 | quiverquant.comQUnicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comUnicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 16, 2026 | seekingalpha.comUnicycive Therapeutics Inc.April 11, 2026 | barrons.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmApril 9, 2026 | prnewswire.comUnicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | globenewswire.comPiper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)April 2, 2026 | theglobeandmail.comUNCY retail buzz explodes 150% this week as traders bet big on experimental drug approvalApril 1, 2026 | msn.comUnicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comKuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law FirmMarch 6, 2026 | newsfilecorp.comNImportant Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your BehalfFebruary 17, 2026 | newsfilecorp.comNUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech SummitFebruary 4, 2026 | finance.yahoo.comUnicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech SummitFebruary 4, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMREO, IMDX, UNCY, and CRBU Company DescriptionsCaribou Biosciences NASDAQ:CRBU$1.60 -0.07 (-3.92%) Closing price 04:00 PM EasternExtended Trading$1.64 +0.04 (+2.76%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Oncocyte NASDAQ:IMDX$5.61 +0.18 (+3.31%) Closing price 04:00 PM EasternExtended Trading$5.62 +0.01 (+0.27%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Mereo BioPharma Group NASDAQ:MREO$0.30 -0.01 (-2.18%) Closing price 04:00 PM EasternExtended Trading$0.30 0.00 (0.00%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Unicycive Therapeutics NASDAQ:UNCY$7.25 -0.44 (-5.72%) Closing price 04:00 PM EasternExtended Trading$7.33 +0.08 (+1.05%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
